425: Alumis and ACELYRIN Announce Merger to Create Immunology Powerhouse

Alumis and ACELYRIN are merging in a stock transaction, creating a combined entity with a diversified pipeline and stronger financial position.

Summary

• Alumis and ACELYRIN have announced a merger agreement where ACELYRIN stockholders will receive 0.4274 shares of Alumis stock for each ACELYRIN share.
• This results in a pro forma ownership of approximately 55% for Alumis stockholders and 45% for ACELYRIN stockholders.
• The combined company will operate under the Alumis name, led by the current Alumis leadership team, and will remain headquartered in South San Francisco.
• The merger is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• The merger aims to create a company with a late-stage portfolio of therapies and increased financial flexibility.
• Alumis's lead program, ESK-001, is in Phase 3 trials for psoriasis and Phase 2b for lupus, with topline data expected in 2026.
• ACELYRIN's lonigutamab, a treatment for thyroid eye disease (TED), will be further evaluated by Alumis to determine the most capital-efficient development plan.
• The combined company's pro forma cash position is estimated at $737 million as of the end of 2024, providing cash runway into 2027.
• Alumis plans to file an IND for a third clinical candidate later this year.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the merger, highlighting the benefits of a diversified pipeline, stronger financial position, and potential for future growth. The management's comments and the overall tone suggest confidence in the combined company's prospects.

Positives

• The merger creates a company with a diversified late-stage pipeline.
• The combined company has a stronger financial position with a cash runway into 2027.
• Alumis's ESK-001 program is progressing well in Phase 3 for psoriasis and Phase 2b for lupus.
• The merger allows for a more efficient use of capital and resources.
• The combined company will benefit from the expertise of both Alumis and ACELYRIN teams.

Negatives

• Alumis will re-evaluate the development plan for lonigutamab, potentially delaying its progress.
• The merger is subject to stockholder approval and customary closing conditions, which could delay or prevent the transaction.
• There are risks associated with integrating the two companies and realizing the expected synergies.

Risks

• The merger may not be completed in a timely manner or at all.
• Required approvals for the transaction may not be received.
• The announcement of the merger could affect Alumis's or ACELYRIN's ability to retain key personnel.
• The merger could divert management's attention from ongoing business operations.
• The anticipated benefits and synergies of the merger may not be fully realized.
• There are risks related to the value of Alumis securities to be issued in the transaction.
• Integration of the transaction post-closing may not occur as anticipated.
• Potential delays in initiating, enrolling or completing preclinical studies and clinical trials.

Future Outlook

The combined company aims to advance its pipeline programs, including ESK-001 and lonigutamab, and achieve key milestones while maintaining capital efficiency. They anticipate a strong financial position to support these efforts.

Management Comments

• Martin Babler: 'What particularly is compelling about this transaction, and well speak more about this in a moment, is that it creates a highly differentiated late-stage portfolio that were well-positioned to advance through multiple upcoming milestones, with significant combined financial strength.'
• Mina Kim: 'This merger follows a thorough strategic review process by our board of directors and the management team to determine the best and most value maximizing path forward for ACELYRIN shareholders and our patients.'
• John Schroer: 'We anticipate the transaction will provide us with cash runway into 2027, beyond our standalone basis of 2026.'

Industry Context

This merger reflects a trend in the biotech industry towards consolidation to create companies with diversified pipelines and stronger financial positions. It allows the combined entity to better compete in the immunology space and navigate the challenges of drug development and commercialization.

Comparison to Industry Standards

• The merger of Alumis and ACELYRIN is similar to other recent biotech mergers aimed at creating larger, more diversified companies.
• Alumis's TYK2 inhibitor program competes with other TYK2 inhibitors in development, such as SOTYKTU from Bristol Myers Squibb.
• ACELYRIN's lonigutamab targets the same pathway as TEPEZZA from Horizon Therapeutics, but with a subcutaneous delivery method.
• The combined company's cash position is comparable to other late-stage biotech companies, providing them with the resources to advance their clinical programs.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger, with ACELYRIN shareholders receiving Alumis stock.
• Employees of both companies may experience changes as a result of the integration.
• Patients may benefit from the development of new therapies for immune-mediated diseases.
• The combined company will have relationships with suppliers, partners, and other stakeholders.

Next Steps

• Alumis and ACELYRIN will seek stockholder approval for the merger.
• Alumis will file a registration statement on Form S-4 with the SEC.
• Alumis will re-evaluate the development plan for lonigutamab.
• Alumis will continue to advance its ESK-001 program in psoriasis and lupus.
• Alumis plans to initiate a Phase 2 clinical trial in multiple sclerosis for A-005 in the second half of the year.
• Alumis expects to file an IND for a third clinical candidate later this year.

Key Dates

Keywords

merger, Alumis, ACELYRIN, immunology, TYK2 inhibitor, lonigutamab, ESK-001, thyroid eye disease, psoriasis, lupus, clinical trials, pipeline, pharmaceuticals, biotech